M.-A. KASPER, A. STENGL, P. OCHTROP, M. GERLACH, T. STOSCHEK, D. SCHUMACHER, J. HELMA, M. PENKERT, E. KRAUSE, H. LEONHARDT*, C. P. R. HACKENBERGER* (LEIBNIZ-FORSCHUNGSINSTITUT FÜR MOLEKULARE PHARMAKOLOGIE, BERLIN, HUMBOLDT UNIVERSITÄT ZU BERLIN, AND LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, GERMANY)

Ethynylphosphonamidates for the Rapid and Cysteine-Selective Generation of Efficacious Antibody–Drug Conjugates
Angew. Chem. Int. Ed. **2019**, *58*, 11631–11636.

Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates

Significance: Antibody–drug conjugates (ADCs) have emerged as a new class of targeted therapeutics. They combine the high potency of cytotoxic drugs with the tumor specificity of monoclonal antibodies. However, the insufficient stability in serum and undesired aggregation often lead to off-target toxicity.

Comment: The researchers report the conjugation of antimitotic agent monomethyl auristatin F (MMAF) to the Her2-targeting antibody trastuzumab by using ethynylphosphonamidate functionalized linker **B**. The resulting ADC showed a drug-to-antibody ratio of 4.6. Furthermore, the use of a phosphonamidate linker bearing diethyleneglycol improved the polarity of the whole linker system. The ADCs had in vivo antitumor activity.

SYNFACTS Contributors: Dirk Trauner, Andrej Shemet
 Synfacts 2019, 15(10), 1189 Published online: 17.09.2019
 DOI: 10.1055/s-0039-1690935; Reg-No.: T08619SF

© 2019, Thieme. All rights reserved.
 Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Category

Chemistry in
 Medicine and
 Biology

Key words

antibodies

bioconjugation

drug delivery

Synfact
 of the
 Month

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.